Sandrine Faivre

20.8k total citations · 9 hit papers
286 papers, 14.9k citations indexed

About

Sandrine Faivre is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sandrine Faivre has authored 286 papers receiving a total of 14.9k indexed citations (citations by other indexed papers that have themselves been cited), including 158 papers in Oncology, 114 papers in Molecular Biology and 83 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sandrine Faivre's work include Hepatocellular Carcinoma Treatment and Prognosis (50 papers), Pancreatic and Hepatic Oncology Research (47 papers) and Lung Cancer Treatments and Mutations (46 papers). Sandrine Faivre is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (50 papers), Pancreatic and Hepatic Oncology Research (47 papers) and Lung Cancer Treatments and Mutations (46 papers). Sandrine Faivre collaborates with scholars based in France, United States and Germany. Sandrine Faivre's co-authors include Éric Raymond, Jan M. Woynarowski, Guido Kroemer, Armand de Gramont, Annemilaï Tijeras‐Raballand, Stephen G. Chaney, Christophe Le Tourneau, Cindy Neuzillet, Esteban Cvitkovic and Jean‐Pierre Armand and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Hepatology.

In The Last Decade

Sandrine Faivre

281 papers receiving 14.6k citations

Hit Papers

Safety, Pharmacokinetic, ... 2005 2026 2012 2019 2005 2006 2007 2005 2014 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer
    2005 934 citations Sandrine Faivre, Catherine Delbaldo et al. Journal of Clinical Oncology profile →
  2. Current development of mTOR inhibitors as anticancer agents
    2006 778 citations Sandrine Faivre, Éric Raymond et al. profile →
  3. Molecular basis for sunitinib efficacy and future clinical development
    2007 546 citations Sandrine Faivre, Éric Raymond et al. profile →
  4. mTOR-targeted therapy of cancer with rapamycin derivatives
    2005 520 citations Sandrine Faivre, Éric Raymond et al. Annals of Oncology profile →
  5. Targeting the TGFβ pathway for cancer therapy
    2014 489 citations Sandrine Faivre, Éric Raymond et al. profile →
  6. Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel for Larynx Preservation
    2009 369 citations Sandrine Faivre et al. profile →
  7. Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
    2011 334 citations E. Maubec, Peter Petrow et al. Journal of Clinical Oncology profile →
  8. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
    2013 314 citations Lisa Licitra, Sylvie Rottey et al. profile →
  9. Molecular therapies for HCC: Looking outside the box
    2020 260 citations Sandrine Faivre et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sandrine Faivre France 58 6.8k 6.7k 3.4k 2.2k 1.7k 286 14.9k
Howard S. Höchster United States 56 8.1k 1.2× 2.4k 0.4× 3.3k 1.0× 1.8k 0.8× 2.0k 1.2× 342 12.0k
Jacqueline Whang‐Peng Taiwan 63 5.0k 0.7× 5.6k 0.8× 3.1k 0.9× 1.8k 0.8× 1.7k 1.0× 319 15.0k
Antonio Russo Italy 55 5.8k 0.8× 4.7k 0.7× 2.3k 0.7× 3.2k 1.4× 1.7k 1.0× 371 11.9k
Éric Raymond France 71 10.9k 1.6× 8.8k 1.3× 4.6k 1.4× 3.0k 1.3× 2.5k 1.4× 369 22.4k
Brigette Ma Hong Kong 53 4.9k 0.7× 2.7k 0.4× 2.3k 0.7× 2.4k 1.1× 1.1k 0.7× 243 10.2k
Alexandra Giatromanolaki Greece 65 4.2k 0.6× 7.6k 1.1× 2.8k 0.8× 5.9k 2.7× 639 0.4× 389 15.3k
Filip Jankú United States 58 6.0k 0.9× 6.7k 1.0× 4.4k 1.3× 4.3k 1.9× 2.4k 1.4× 430 14.9k
Patrick Schöffski Belgium 68 9.6k 1.4× 4.8k 0.7× 9.5k 2.8× 2.2k 1.0× 1.9k 1.1× 510 19.4k
Rosemarie Mick United States 72 6.2k 0.9× 3.5k 0.5× 2.6k 0.8× 2.1k 1.0× 1.5k 0.9× 265 14.4k
G. Milano France 57 7.8k 1.1× 4.1k 0.6× 3.1k 0.9× 1.5k 0.7× 1.4k 0.8× 392 12.3k

Countries citing papers authored by Sandrine Faivre

Since Specialization
Citations

This map shows the geographic impact of Sandrine Faivre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandrine Faivre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandrine Faivre more than expected).

Fields of papers citing papers by Sandrine Faivre

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandrine Faivre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandrine Faivre. The network helps show where Sandrine Faivre may publish in the future.

Co-authorship network of co-authors of Sandrine Faivre

This figure shows the co-authorship network connecting the top 25 collaborators of Sandrine Faivre. A scholar is included among the top collaborators of Sandrine Faivre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandrine Faivre. Sandrine Faivre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Desîlets, Antoine, Justin Lucas, Lisa Licitra, et al.. (2025). Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 Study. Targeted Oncology. 20(2). 299–310.
2.
Beddok, Arnaud, Eunike Velleuer, Ruud H. Brakenhoff, et al.. (2025). Strategies for early detection and detailed characterization of oral lesions and head and neck squamous cell carcinoma in Fanconi anemia patients. Cancer Letters. 617. 217529–217529. 2 indexed citations
3.
Pan, Hongming, Jean Frédéric Blanc, Véronique Grando, et al.. (2024). Activity of Tepotinib in Hepatocellular Carcinoma With High-Level MET Amplification: Preclinical and Clinical Evidence. JCO Precision Oncology. 8(8). e2300328–e2300328. 6 indexed citations
4.
Soulières, Denis, et al.. (2021). The BURAN study of buparlisib (AN2025) in combination with paclitaxel compared to paclitaxel alone, in patients with recurrent or metastatic head and neck squamous cell carcinoma.. Journal of Clinical Oncology. 39(15_suppl). TPS6090–TPS6090. 4 indexed citations
5.
Raymond, Éric, Catherine Thiéblemont, S. Alran, & Sandrine Faivre. (2020). Impact of the COVID-19 Outbreak on the Management of Patients with Cancer. Targeted Oncology. 15(3). 249–259. 93 indexed citations
6.
Delord, Jean‐Pierre, Antoîne Italiano, Ahmad Awada, et al.. (2020). Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. Targeted Oncology. 16(1). 37–46. 8 indexed citations
7.
Lebbé, Célèste, Antoîne Italiano, Nadine Houédé, et al.. (2020). Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. Targeted Oncology. 16(1). 47–57. 10 indexed citations
8.
Soulières, Denis, Lisa Licitra, Ricard Mesı́a, et al.. (2018). Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1. Clinical Cancer Research. 24(11). 2505–2516. 34 indexed citations
9.
Salomé, Christophe, Nigel Ribeiro, Frédéric Thuaud, et al.. (2014). Benzofuran derivatives as anticancer inhibitors of mTOR signaling. European Journal of Medicinal Chemistry. 81. 181–191. 35 indexed citations
10.
Maubec, E., Peter Petrow, Isabelle Scheer-Senyarich, et al.. (2011). Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin. Journal of Clinical Oncology. 29(25). 3419–3426. 334 indexed citations breakdown →
11.
Handra‐Luca, Adriana, Claude Lesty, Pascal Hammel, et al.. (2011). Biological and Prognostic Relevance of Mitogen-Activated Protein Kinases in Pancreatic Adenocarcinoma. Pancreas. 41(3). 416–421. 28 indexed citations
12.
Hammel, Pascal, Daniel Castellano, Eric Van Cutsem, et al.. (2011). Evaluation of Progression-Free Survival by Blinded Independent Central Review in Patients With Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors Treated With Sunitinib or Placebo. Pancreas. 40(2). 327–327. 2 indexed citations
13.
Lovejoy, Katherine S., Maria Serova, Ivan Bièche, et al.. (2011). ANTICANCER ACTIVITY OF PYRIPLATIN, A MONOFUNCTIONAL CATIONIC PLATINUM(II) COMPOUND, IN HUMAN CANCER CELLS. Europe PMC (PubMed Central). 71 indexed citations
14.
Malouf, Gabriel G., Chantal Dreyer, Nathalie Guedj, et al.. (2009). Facteurs pronostiques des cholangiocarcinomes : apport des données récentes de biologie moléculaire. Bulletin du Cancer. 96(4). 405–415. 1 indexed citations
15.
Ghoul, Aïda, Maria Serova, Lucile Astorgues‐Xerri, et al.. (2009). Epithelial-to-Mesenchymal Transition and Resistance to Ingenol 3-Angelate, a Novel Protein Kinase C Modulator, in Colon Cancer Cells. Cancer Research. 69(10). 4260–4269. 44 indexed citations
16.
Dreyer, Chantal, Éric Raymond, & Sandrine Faivre. (2009). Les thérapies ciblées et leurs indications dans les tumeurs solides. La Revue de Médecine Interne. 30(5). 416–424. 4 indexed citations
17.
Faivre, Sandrine, Catherine Delbaldo, Karina Vera, et al.. (2005). Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer. Journal of Clinical Oncology. 24(1). 25–35. 934 indexed citations breakdown →
18.
Spano, Jean‐Philippe & Sandrine Faivre. (2003). [Non-AIDS-related malignancies: prognostic and treatment].. PubMed. 90(5). 413–8. 1 indexed citations
19.
Spano, Jean‐Philippe & Sandrine Faivre. (2003). Tumeurs malignes non associées au VIH : pronostic et traitement. Bulletin du Cancer. 90(5). 413–418. 1 indexed citations
20.
Raymond, Éric, Michel Fabbro, Valérie Boige, et al.. (2003). Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. Annals of Oncology. 14(4). 603–614. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Howard S. Höchster Breakdown of academic impact, for papers by Jacqueline Whang‐Peng Breakdown of academic impact, for papers by Antonio Russo Breakdown of academic impact, for papers by Éric Raymond Breakdown of academic impact, for papers by Brigette Ma Breakdown of academic impact, for papers by Alexandra Giatromanolaki Breakdown of academic impact, for papers by Filip Jankú Breakdown of academic impact, for papers by Patrick Schöffski Breakdown of academic impact, for papers by Rosemarie Mick Breakdown of academic impact, for papers by G. Milano
Rankless by CCL
2026